U.S. stock market midday update: Positive clinical data fails to mask financial concerns, Lexeo Therapeutics stock price plummets 12.56%

U.S. Stock Market Midday Update Lexeo Therapeutics fell 12.56%. Based on recent news, On January 12, Lexeo Therapeutics announced mid-term data from its Phase I/II clinical trial of the LX2020 drug, showing that the drug was well tolerated in most participants and led to a dose-dependent increase in PKP2 protein expression. However, despite these positive clinical developments, concerns about its financial performance remain, leading to a decline in stock price. Source: Company announcement On January 11, analysts pointed out four warning signals for Lexeo Therapeutics, two of which are particularly unfavorable. These warning signals may include poor financial condition and high cash consumption, further exacerbating investor concerns. Source: Analyst report On January 13, despite the company receiving a capital injection of $135 million and making progress in regulatory and clinical aspects, the market's limited support for its valuation due to the company's continued lack of revenue and widening losses led to continued pressure on its stock price. Source: Market analysis Gene therapy industry has been highly volatile recently, and investors should exercise caution. Top Stocks by Industry Trading Volume Moderna rose 15.56%. Based on recent key news: On January 12, Moderna raised its revenue forecast for 2025 to $1.9 billion, exceeding analyst expectations, which drove the stock price up. The company expects a 10% revenue growth in 2026 and plans to launch new products and reduce operating expenses to support growth. Source: Reuters On January 12, Moderna announced a $200 million reduction in its 2025 operating expense forecast, with the adjusted expected range being $5 billion to $5.2 billion, further enhancing market confidence. Source: Bloomberg On January 12, Moderna expects to receive regulatory approval for its flu vaccine and flu-COVID combined vaccine in 2026, driving the stock price up. Source: WSJ The vaccine industry is becoming increasingly competitive, with significant policy impacts. AbbVie fell 0.47%, with increased trading volume. Based on recent key news: On January 13, AbbVie reached an agreement with the U.S. government to commit to lowering the prices of certain drugs and investing $100 billion domestically in exchange for specific tariff exemptions. This move aims to improve access to medications for the American public and reduce burdens, causing stock price fluctuations. On January 12, AbbVie signed a licensing agreement with Rongchang Biologics, obtaining exclusive rights for the development, production, and commercialization of RC148 outside of Greater China. Upon the agreement's effectiveness, Rongchang Biologics will receive a $650 million upfront payment, drawing market attention to AbbVie. On January 13, discussions on licensing deals and pricing policies were highlighted at the JP Morgan Healthcare Conference, which may impact AbbVie. Changes in industry policies affect market sentiment Regeneron Pharmaceuticals fell 1.62%. Based on recent news, On January 13, Jefferies raised the target price for Regeneron Pharmaceuticals from $870 to $885. This move reflects analysts' confidence in the company's future growth potential, despite a short-term decline in stock price. On January 11, MarketBeat reported that Regeneron Pharmaceuticals was not included in the list of top five stocks recommended by leading analysts. Although the company still maintains a moderate buy rating, market preference for other stocks may affect investor interest in Regeneron. No other significant news recently. The pharmaceutical industry has been quite volatile lately and requires attention. Stocks ranked at the top of the industry by market capitalization Amgen fell 0.73%, with increased trading volume. Based on recent key news: On January 13, Amgen announced a collaboration with Ro to conduct research to assess the real-world coverage of GLP-1. This initiative aims to identify unmet needs through observational studies and assist in the development of future therapies, driving stock price volatility. On January 13, Amgen's experimental obesity drug MariTide showed significant reductions in blood sugar and weight in a 24-week study. This result has bolstered market confidence in its product line, impacting stock price. On January 13, analysts maintained a "Neutral" or "Market Perform" rating for Amgen, but BMO raised the target price to $372, reflecting optimistic expectations for its product line. The biopharmaceutical industry is facing intensified competition, and policy changes need to be monitored